This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
English to Spanish: Inhibitors in haemophilia: pathophysiology / Inhibidores en hemofilia: fisiopatología
Source text - English Summary. Development of inhibitors to coagulation factors is one of the major problems faced by people with haemophilia. Up to a third of patients, following treatment with factor concentrates, will develop an antibody (inhibitor) to that factor, rendering it inactive, and leaving the patient at risk from life-threatening bleeding. Evidence shows that this immune response is T-cell-dependent, but as yet, the epitopes responsible have not been identified. Risk for inhibitor development is highest within the first 50 days of treatment, with reactions being rare after 200 days. The risk is mediated by the major histocompatibility complex class of the patient, and by mutations in the factor VIII genotype, with large deletions conferring greatest risk.
Keywords
FVIII • haemophilia • inhibitors
Translation - Spanish Resumen. Uno de los mayores problemas que enfrentan las personas con hemofilia es el desarrollo de inhibidores de los factores de coagulación. Luego del tratamiento con concentrados de factor, hasta un tercio de los pacientes desarrolla un anticuerpo (inhibidor) contra ese factor, inactivándolo y dejando al paciente desprotegido ante hemorragias que puedan poner en riesgo su vida. La evidencia muestra que esta respuesta inmune depende de las células T, aunque hasta el momento no se han identificado los epitopes responsables.
El riesgo de desarrollar inhibidores es más alto dentro de los primeros 50 días de tratamiento y es muy poco probable que haya reacciones después de los 200 días. El riesgo está mediado por la clase de complejo mayor de histocompatibilidad del paciente y por las mutaciones en el genotipo del factor VIII, adjudicándosele el mayor riesgo a las deleciones importantes.
Palabras clave: FVIII, hemofilia, inhibidores
More
Less
Experience
Years of experience: 10. Registered at ProZ.com: Sep 2008.
I have been working in the following areas of specialization for the last ten years:
- Hematology (hemophilia, clinical records, MD's speeches, presentations and CVs, research study protocols). -Speech therapy (speech-language disorders and therapy, linguistics).
My Rates depend on the characteristics of each project. For more information, please contact me at: [email protected]
Thank you for your interest in my profile!
Ana
Keywords: English, Spanish, health care, health, medicine, hematology, hemophilia, thrombosis, hemostasis, bleeding. See more.English, Spanish, health care, health, medicine, hematology, hemophilia, thrombosis, hemostasis, bleeding, coagulation, clinical records, MD's speeches, presentations, curriculum, curricula, CVs, resume, resumes, research study protocols, speech-language disorders and therapy, language, linguistics, phonetics, phonology, aphasiology.. See less.
Expertise